NSCLC: Advantage for mutation-specific first-line combination therapy

If NSCLC patients have certain tumor mutations in the EGFR gene, first-line therapy with the bispecific antibody amivantamab plus the TKI lazertinib is advantageous: the risk of tumor progression or death is 30% lower than with osimertinib.